Key result
Anti-GM1 IgM antibodies were detected in 23% of patients with motor neuron disease and 19% of patients with neuropathy, compared to 7% of controls.
Why the study?
Is the frequency of anti-GM1 IgM antibodies higher in patients with motor neuron disease and neuropathy compared to controls?
Case-Control (n=232)
Is the frequency of anti-GM1 IgM antibodies higher in patients with motor neuron disease and neuropathy compared to controls?
Answers are grounded in this paper and cite their sources.
Anti-GM1 IgM antibodies are more frequently found in patients with motor neuron disease and neuropathy compared to controls, though their pathogenic role remains unclear.
We found anti-GM1 IgM antibodies in 23% of 56 patients with motor neuron disease (MND), in 19% of 69 patients with neuropathy, and in 7% of 107 controls with other neurologic and nonneurologic diseases. Most of these patients had anti-GM1 IgM antibody titers of 1:80 or less; slightly higher antibody titers (up to 1:640) were found in 3 patients, 1 with MND and 2 with neuropathy, and very high titers (1:20,480) in a patient with MND and an IgM kappa M protein that reacted with GM1, GD1b, and asialo GM1. Six other patients with anti-GM1 IgM that also bound to GD1b. Reactivity with GD1b did not correlate with anti-GM1 titers but was only present in patients with MND or neuropathy. Anti-GM1 IgM antibodies may be a normal constituent of the human antibody repertoire but their frequency and, in some cases, their levels are higher in patients with MND and neuropathy. The origin and the pathogenetic role of these antibodies in neural impairment remain to be established.
No takes yet. Share an insight, caveat, or question.
Nobile‐Orazio et al. (1990) conducted a case-control in Motor neuron disease and neuropathy (n=232). Motor neuron disease and neuropathy vs. Controls with other neurologic and nonneurologic diseases was evaluated on Presence of anti-GM1 IgM antibodies. Anti-GM1 IgM antibodies were detected in 23% of patients with motor neuron disease and 19% of patients with neuropathy, compared to 7% of controls.
Synapse has enriched 10 related papers. Consider them for comparative context: